A 10-year multicenter study highlights that cardiac structural complications (CSCs) affect 2.1% of TAVR recipients. With a 35% 30-day mortality rate and no decline in incidence over a decade, these events remain a formidable challenge for interventional cardiology teams despite advancing technology.